Nocturia - Pipeline Review, H1 2018

Detailed TOC of Nocturia - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Nocturia - Overview
Nocturia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nocturia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nocturia - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Ferring International Center SA
Sanwa Kagaku Kenkyusho Co Ltd
Vantia Therapeutics
Nocturia - Drug Profiles
(acetaminophen + ibuprofen) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7035 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-7398 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
desmopressin acetate ODT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FE-201836 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fedovapagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nocturia - Dormant Projects
Nocturia - Product Development Milestones
Featured News & Press Releases
Aug 08, 2017: Ferring Pharmaceuticals: The Scottish Medicines Consortium Approves Use of NOQDIRNA (oral lyophilisate desmopressin), the First Licensed Treatment for Nocturia due to Idiopathic Nocturnal Polyuria in Adults
Aug 07, 2017: Noqdirna is accepted for restricted use within NHS Scotland
Feb 13, 2017: Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer